Synthesis and cytotoxicity studies of novel anion-exchanged Titanocene Y derivatives

被引:2
作者
Claffey, James [1 ]
Deally, Anthony [1 ]
Gleeson, Brendan [1 ]
Patil, Siddappa [1 ]
Tacke, Matthias [1 ]
机构
[1] Univ Coll Dublin, UCD Sch Chem & Chem Biol, Conway Inst Biomol & Biomed Res, Ctr Synth & Chem Biol, Dublin 4, Ireland
关键词
anticancer drugs; cisplatin; carboplatin; Titanocene Y; metal carboxylates; LLC-PK; ANTICANCER DRUGS; ANTITUMOR-ACTIVITY; DICHLORIDE; CARCINOMA; COMPLEXES; CANCER; TRIAL;
D O I
10.1002/aoc.1665
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Starting from the potential anticancer drug candidate Titanocene Y {bis-[(4-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride}, anion exchange experiments were performed using silver malonate (1a) or silver cyclobutane-1,1-malonate (1b) in order to yield bis-[(4-methoxy-benzyl)cyclopentadienyl]titanium(IV) malonate (2a) and bis-[(4-methoxy-benzyl) cyclopentadienyl]titanium(IV) cyclobutane-1,1-malonate (2b). In addition, Titanocene Y was reacted with salicylic acid (3a) or 3,5-dinitro-salicylic acid (3b) in the presence of diethylamine to synthesize bis-[(4-methoxy-benzyl)cyclopentadienyl]titanium( IV) salicylate (4a) or bis-[(4-methoxy-benzyl)cyclopentadienyl]titanium(IV) 3,5-dinitro-salicylate (4b). These titanocenes had their cytotoxicity investigated through preliminary in vitro testing on the LLC-PK (pig kidney epithelial) cell line in an MTT-based assay in order to determine their IC50 values. Titanocenes 2a-b and 4a were found to have IC50 values of 74 (+/- 13) mu M, 18 (+/- 5) mu M and 49 (+/- 11) mu M on the LLC-PK cell line, while compound 4b was found to have lost all its cytotoxic activity on this cell line. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:675 / 679
页数:5
相关论文
共 18 条
[1]   Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs [J].
Allen, OR ;
Croll, L ;
Gott, AL ;
Knox, RJ ;
McGowan, PC .
ORGANOMETALLICS, 2004, 23 (02) :288-292
[2]   Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis [J].
Ang, Wee Han ;
Daldini, Elisa ;
Scolaro, Claudine ;
Scopelliti, Rosario ;
Juillerat-Jeannerat, Lucienne ;
Dyson, Paul J. .
INORGANIC CHEMISTRY, 2006, 45 (22) :9006-9013
[3]   Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo [J].
Bannon, J. H. ;
Fichtner, I. ;
O'Neill, A. ;
Pampillon, C. ;
Sweeney, N. J. ;
Strohfeldt, K. ;
Watson, R. W. ;
Tacke, M. ;
Mc Gee, M. M. .
BRITISH JOURNAL OF CANCER, 2007, 97 (09) :1234-1241
[4]  
Caruso F, 2004, MET IONS BIOL SYST, V42, P353
[5]   Oxali-titanocene Y:: A potent anticancer drug [J].
Claffey, James ;
Hogan, Megan ;
Mueller-Bunz, Helge ;
Pampillon, Clara ;
Tacke, Matthias .
CHEMMEDCHEM, 2008, 3 (05) :729-731
[6]   Pseudo-halide derivatives of titanocene Y: synthesis and cytotoxicity studies [J].
Claffey, James ;
Deally, Anthony ;
Gleeson, Brendan ;
Hogan, Megan ;
Mendez, Luis Miguel Menendez ;
Mueller-Bunz, Helge ;
Patil, Siddappa ;
Wallis, Denise ;
Tacke, Matthias .
METALLOMICS, 2009, 1 (06) :511-517
[7]   Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice [J].
Fichtner, Iduna ;
Behrens, Diana ;
Claffey, James ;
Gleeson, Brendan ;
Hogan, Megan ;
Wallis, Denise ;
Weber, Holger ;
Tacke, Matthias .
LETTERS IN DRUG DESIGN & DISCOVERY, 2008, 5 (08) :489-493
[8]  
*GAUSS INC, 2004, GAUSS 03 REV C 02
[9]   Alkyloxy- and aryloxy-titanocenes:: Synthesis, solid-state structure and cyclic voltammetric studies [J].
Koecher, Stefan ;
Walfort, Bernhard ;
Rheinwald, Gerd ;
Rueffer, Tobias ;
Lang, Heinrich .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2008, 693 (20) :3213-3222
[10]   Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer [J].
Kroger, N ;
Kleeberg, UR ;
Mross, K ;
Edler, L ;
Sass, G ;
Hossfeld, DK .
ONKOLOGIE, 2000, 23 (01) :60-62